| Title |
A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44
|
|---|---|
| Published in |
Cancer Immunology, Immunotherapy, November 2006
|
| DOI | 10.1007/s00262-006-0244-5 |
| Pubmed ID | |
| Authors |
Danièle Godelaine, Javier Carrasco, Francis Brasseur, Bart Neyns, Kris Thielemans, Thierry Boon, Aline Van Pel |
| Abstract |
A panel of cytolytic T lymphocyte (CTL) clones was isolated from metastases and blood samples of a melanoma patient vaccinated with MAGE-3.A1-pulsed autologous dendritic cells. We report here the identification of a new antigen encoded by the MAGE-C2 cancer-germline gene. This antigen is recognized by some of these CTL on HLA-B*4403. The sequence of the peptide is SESIKKKVL. It is processed in various melanoma cell lines expressing MAGE-C2 and HLA-B*4403. Because of the expression pattern of gene MAGE-C2, this new antigen is strictly tumor-specific and could therefore be used for peptide-based antitumoral vaccination. |
Mendeley readers
The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 19 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Professor > Associate Professor | 5 | 26% |
| Researcher | 4 | 21% |
| Student > Ph. D. Student | 4 | 21% |
| Student > Master | 2 | 11% |
| Other | 1 | 5% |
| Other | 2 | 11% |
| Unknown | 1 | 5% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 8 | 42% |
| Medicine and Dentistry | 7 | 37% |
| Immunology and Microbiology | 1 | 5% |
| Computer Science | 1 | 5% |
| Unknown | 2 | 11% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 May 2016.
All research outputs
#4,696,560
of 22,788,370 outputs
Outputs from Cancer Immunology, Immunotherapy
#505
of 2,881 outputs
Outputs of similar age
#12,567
of 69,217 outputs
Outputs of similar age from Cancer Immunology, Immunotherapy
#6
of 15 outputs
Altmetric has tracked 22,788,370 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,881 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one has gotten more attention than average, scoring higher than 72% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 69,217 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.